OLMA

$7.33+8.43%visit website

Olema Pharmaceuticals, Inc.

Market Cap

$641M

Live price × SEC shares (Aug 6, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.08

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	39,951	43,220	49,232	57,785	190,188
Total operating expenses	45,877	50,084	57,986	67,179	221,126
Operating income	(45,877)	(50,084)	(57,986)	(67,179)	(221,126)
Net income	(42,217)	(46,061)	(53,089)	(63,200)	(204,567)
EPS (basic) ($)	(0.49)		(0.52)	(0.61)	(2.12)
EPS (diluted) ($)	(0.49)		(0.52)	(0.61)	(2.12)
Weighted avg. shares (basic)	85,732		102,800	104,454
Weighted avg. shares (diluted)	85,732		102,800	104,454

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 10, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 22 more quarters, back to Mar 2020, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

77%

W/W +16.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-07-24	2026-07-27	Harmon Cyrus	Director	Sale	12.5K	$11.71	$146K	702.8K	View
2026-07-23	2026-07-27	Harmon Cyrus	Director	Sale	12.5K	$11.58	$145K	715.3K	View
2026-03-04	2026-03-05	Mitchell Shawnte	CHIEF LEGAL OFFICER	Sale	25.0K	$24.25	$606K	0	View
2026-03-03	2026-03-05	Mitchell Shawnte	CHIEF LEGAL OFFICER	Sale	15.0K	$23.01	$345K	0	View

Gov Contracts

Agency	Amount	Awarded
Department of Defense	$1.2B	2013-10-31

Recent News

Olema Pharmaceuticals, Inc. (OLMA) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-04

Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium

Yahoo · 2026-11-04

Olema will present data on three breast cancer drug combinations in San Antonio this December.

Stock Titan · 2026-11-04

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo · 2026-11-03

Olema Oncology to Participate in Upcoming Investor Conferences

Yahoo · 2026-11-02

Four fireside chats are planned across Boston, New York and London

Stock Titan · 2026-11-02

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Falls 6.6% - Here's What Happened

MarketBeat · 2026-10-23

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology

Yahoo · 2026-10-19

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

Yahoo · 2026-10-16

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga · 2026-10-14

SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight

Yahoo Finance · 2026-10-05

Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results

Yahoo Finance · 2026-09-14

$OLMA stock is down 12% today. Here's what we see in our data.

Quiver Quantitative · 2026-08-11

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

Yahoo Finance · 2026-08-10

Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?

Yahoo Finance · 2026-06-30

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-07-24	Harmon Cyrus	S	12,500	$146,425
2026-07-23	Harmon Cyrus	S	12,500	$144,737.5
2026-03-04	Mitchell Shawnte	S	24,767	$600,599.75
2026-03-04	Mitchell Shawnte	S	233	$5,752.77
2026-03-03	Mitchell Shawnte	S	15,000	$345,150

OLMA

Financial Statements

Signals

Factor Profile

Gov Contracts

Recent News

Olema Pharmaceuticals, Inc. (OLMA)

Reporting Insiders

Factor Profile